Evaluation of Long-Acting Muscarinic Antagonists in COPD

Inclusion Criteria: * Male and female volunteers aged 40-80 years with moderate to severe COPD (GOLD Stage 2, 3). * On inhaled corticosteroids / long-acting beta agonists * FEV1 30-80% predicted and FEV1/FVC \<70%. * Smoking history ≥10 pack-years. * Ability to give informed consent * Agreement for their General Practitioner to be made aware of study participation and to receive feedback as relevant to the participant's well being Exclusion Criteria: * Other respiratory diseases such as asthma, bronchiectasis or allergic bronchopulmonary aspergillosis * A COPD exacerbation or respiratory tract infection requiring systemic steroids and/or antibiotics within 1 month of the study commencement (3 months if hospitalisation has been required) * Any clinically significant medical condition that may endanger the health or safety of the participant * Known or suspected sensitivity to/intolerance of investigational medicinal product * Patients with prostatic hyperplasia, bladder outflow obstruction or glaucoma * Pregnancy or lactation * Unable to comply with the procedures of the protocol